Major Chinese drug makers are continuing to leap into the fray of the already packed PD-1/L1 class of agents. While China’s regulator signalled a tightening of reviews for immuno-oncology therapies in 2021, the latecomers are betting that certain indications will be less crowded.
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Cervical Cancer, SCLC Eyed
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
